SCHEMBL17135367

SCHEMBL17135367

CCCCCCCCCCCCCCCCCC(=O)OCC(CO)(CO)NC(=O)CCCCCCCCCCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.60
DGKA P23743 1/20 0.50
PAM P19021 2/20 0.46
LMNA P02545 2/20 0.45
KDM4E B2RXH2 1/20 0.45
DUSP3 P51452 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TSHR P16473 1/20 0.44
MAPT P10636 1/20 0.44
HSP90AA1 P07900 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCE Q02156 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCD Q05655 1/20 0.43
DNM1 Q05193 1/20 0.43
ALDH1A1 P00352 1/20 0.43
FAAH O00519 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135359 1.00 HRH3 (0.60) HRH3DGKAPAMLMNAKDM4E
SCHEMBL17135363 1.00 HRH3 (0.60) HRH3DGKAPAMLMNAKDM4E
SCHEMBL17135366 1.00 HRH3 (0.60) HRH3DGKAPAMLMNAKDM4E
SCHEMBL17169820 1.00 HRH3 (0.60) HRH3DGKAPAMLMNAKDM4E
SCHEMBL17160790 1.00 HRH3 (0.60) HRH3DGKAPAMLMNAKDM4E
SCHEMBL17135368 1.00 HRH3 (0.60) HRH3DGKAPAMLMNAKDM4E
SCHEMBL17169805 1.00 HRH3 (0.60) HRH3DGKAPAMLMNAKDM4E
SCHEMBL17135357 0.92 HRH3 (0.75) HRH3DGKAPRKCAPRKCEPRKCQ
SCHEMBL17135358 0.92 HRH3 (0.75) HRH3DGKAPRKCAPRKCEPRKCQ
SCHEMBL20543226 0.92 HRH3 (0.55) HRH3DGKAPAMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150290099-A1 NOVEL PSEUDOCERAMIDE COMPOUND AND PRODUCTION METHOD FOR SAME AMOREPACIFIC CORPORATION (KR) 2015-10-15 US claimed
EP-2927211-A1 NOVEL PSEUDOCERAMIDE COMPOUND AND PRODUCTION METHOD FOR SAME Amorepacific Corporation (KR) 2015-10-07 EP claimed
US-20150290099-A1 NOVEL PSEUDOCERAMIDE COMPOUND AND PRODUCTION METHOD FOR SAME AMOREPACIFIC CORPORATION (KR) 2015-10-15 US disclosed
EP-2927211-A1 NOVEL PSEUDOCERAMIDE COMPOUND AND PRODUCTION METHOD FOR SAME Amorepacific Corporation (KR) 2015-10-07 EP disclosed
CN-104854081-A Novel ceramide compound and process for producing the same AMOREPACIFIC CORP 2015-08-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290099-A1 NOVEL PSEUDOCERAMIDE COMPOUND AND PRODUCTION METHOD FOR SAME ASAH2, ACER2, ASAH1 HRH3 320/4885DGKA 363/4885PAM 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.